Archives of Gynecology and Obstetrics

, Volume 284, Issue 2, pp 411–419 | Cite as

Comparison of Pueraria mirifica 25 and 50 mg for menopausal symptoms

  • Phongthorn VirojchaiwongEmail author
  • Visut Suvithayasiri
  • Arunporn Itharat
General Gynecology



To compare Pueraria mirifica 25 and 50 mg dosages to relieve menopausal symptoms.


A double-blind study was conducted on 52 hysterectomized women with menopausal symptoms who had an indication for hormone therapy. The women were randomly allocated into two groups receiving either Pueraria mirifica 25 mg tablet (Arm A; n = 26) or Pueraria mirifica 50 mg (Arm B; n = 26) for 6 months. Menopausal symptoms, physical examination findings, and laboratory data were recorded at baseline. Symptoms were reevaluated at 3 and 6 months, while physical and laboratory examinations were evaluated at 1 month and at the end of treatment. A modified Green climacteric scale was used to evaluate menopausal symptoms; a score of ≥15 indicated estrogen deficiency.


All women completed the study. Mean baseline climacteric scores of women who received 25 and 50 mg were: 24.19 ± 9.11 versus 23.19 ± 7.89, respectively (p = 0.674). After 3 and 6 months of treatment, scores were 17.92 ± 10.40 versus 15.35 ± 8.44 (p = 0.332) and 14.08 ± 10.30 versus 12.46 ± 6.38 (p = 0.500), respectively. No significant side effects were observed with Pueraria mirifica 25 or 50 mg.


Both dosages of Pueraria mirifica were similarly effective and safe in the treatment of menopausal symptoms.


Pueraria mirifica Modified Green climacteric scale Menopausal symptoms 



This study was supported by a grant from The Thai Traditional Medical Knowledge Fund, The Institute of Thai Traditional Medicine, Ministry of Public Health of Thailand. The sponsors were not involved in any aspect of this research. The authors would like to thank Dr. Budsaba Wiriyasirivaj and Dr. Sumonmal Manusirivithaya for their assistance in statistical analysis and Dr. Siriwan Tangjitgamol for the manuscript preparation.

Conflict of interest

The authors declare that we have no conflict of interest.


  1. 1.
    Shuster LT, Rhodes DJ, Gostout BS, Grossardt BR, Rocca WA (2010) Premature menopause or early menopause: long-term health consequences. Maturitas 65(2):161–166PubMedCrossRefGoogle Scholar
  2. 2.
    North American Menopause Society (2007) Menopause practice: a clinician’s guide, 3rd ed. Cleveland, OH, North American Menopause Society, pp 9–18Google Scholar
  3. 3.
    Santoro N (2008) Symptoms of menopause: hot Flushes. evidence-based approach to menopause. Clin Obstet Gynecol 51:539–548PubMedCrossRefGoogle Scholar
  4. 4.
    Knight DC, Eden JA (1996) A review of the clinical effects of phytoestrogens. Obstet Gynecol 87(5):897–904PubMedGoogle Scholar
  5. 5.
    Dewicks PM (1995) Isoflavonoids. In: Harborne JB (ed) The flavonoid. Dhapman & Hall, London, pp 117–238Google Scholar
  6. 6.
    Lamlertkittikul S, Chandeying V (2004) Effectiveness and safety of Pueraria mirifica (Kwao Kruea Khao) for the treatment of vasomotor symptoms in perimenopausal women: phase II study. J Med Assoc Thai 87:33–40PubMedGoogle Scholar
  7. 7.
    Sukavaj T (1949) Herbal medicine. Thai J Med Sci 3:104–110Google Scholar
  8. 8.
    Urasopon N, Hamada Y, Asaoka K, Cherdshewasart W, Malaivijitnond S (2007) Pueraria mirifica, a phytoestrogen-rich herb, prevents bone loss in orchidectomized rats. Maturitas 56:322–331PubMedCrossRefGoogle Scholar
  9. 9.
    Urasopon N, Hamada Y, Cherdshewasart W, Malaivijitnond S (2008) Preventive effects of Pueraria mirifica on bone loss in ovariectomized rats. Maturitas 59:137–148PubMedCrossRefGoogle Scholar
  10. 10.
    Cherdshewasart W, Traosup V, Picha P (2008) Determination of the estrogenic activity of wild phytoestrogen-rich Pueraria mirifica MCF-7 proliferation assay. J Reprod Dev 4:63–67CrossRefGoogle Scholar
  11. 11.
    Chandeying V, Lamlertkittikul S (2007) Challenges in the conduct of Thai herbal scientific study: effectiveness and safety of phytoestrogen, Pueraria mirifica (Kwao Kuer Kao), phase I, in the alleviation of climacteric symptoms in perimenopausal women. J Med Assoc Thai 90:1274–1280PubMedGoogle Scholar
  12. 12.
    Chandeying V, Sangthawan M (2007) Effectiveness comparison of Pueraria mirifica (PM) against conjugated equine estrogen (CEE) with/without medroxyprogesterone acetate (MPA) in the treatment of climacteric symptoms in perimenopausal women: phase III study. J Med Assoc Thai 90:1720–1726PubMedGoogle Scholar
  13. 13.
    Speroff L, Fritz MA (2005) Clinical gynecologic endocrinology and infertility, 7th edn. Williams & Wilkins, Philadelphia, Lippincott, pp 689–777Google Scholar
  14. 14.
    Smitasiri Y, Junyatum U, Songjitsawad A, Sripromma P, Trisrisilp S, Anuntalabhochai S (1986) Postcoital antifertility effects of Pueraria mirifica in rats. J Sci Fac Chiang Mai Univ 13:19–28Google Scholar
  15. 15.
    MacLennan A (1996) Symptoms and signs of the climacteric. In: Wren BG, Nachtigall LE (eds) Clinical management of the menopause. McGraw-Hill, Roseville, pp 7–15Google Scholar
  16. 16.
    Manonai J, Chittacharoen A, Udomsubpayakul U, Theppisai H, Theppisai U (2008) Effects and safety of Pueraria mirifica on lipid profiles and biochemical markers of bone turnover rates in healthy postmenopausal women. Menopause 15:530–535PubMedCrossRefGoogle Scholar
  17. 17.
    Ettinger B (2005) Vasomotor symptom relief versus unwanted effects: role of estrogen dosage. Am J Med 118 (Suppl 12B):74–8Google Scholar
  18. 18.
    Coope J, Thomson JM, Poller L (1975) Effects of “natural oestrogen” replacement therapy on menopausal symptoms and blood clotting. Br Med J 4:139–143PubMedCrossRefGoogle Scholar
  19. 19.
    Klaiber EL, Broverman DM, Vogel W, Kobayashi Y (1979) Estrogen therapy for severe persistent depression women. Arch Gen Psychiatry 36(5):550–554PubMedGoogle Scholar
  20. 20.
    Mundy GR (2007) Osteoporosis and inflammation. Nutr Rev 65(12 Pt 2): S147–S151Google Scholar
  21. 21.
    Wang KC, Lin YF, Qin CH, Chen TL, Chen CH (2010) Bisphenol-A interferes with estradiol-mediated protection in osteoarthritic chondrocytes. Toxicol Lett 5; 198(2):127–133Google Scholar
  22. 22.
    Maltais ML, Desroches J, Dionne IJ (2009) Changes in muscle mass and strength after menopause. J Musculoskelet Neuronal Interact 9(4):186–197PubMedGoogle Scholar
  23. 23.
    Thomas TN, Rhodin JA, Clark L, Garces A, Bryant M (2003) A comparison of the anti-inflammatory activities of conjugated estrogens and 17-beta estradiol. Inflamm Res 52(11):452–460PubMedCrossRefGoogle Scholar
  24. 24.
    Dijsselbloem N, Vanden BW, De NA, Haegeman G (2004) Soy isoflavones phyto-pharmaceuticals in interleukin-6 affections. Multi-purpose nutraceuticals at the crossroad of hormone replacement, anti-cancer and anti-inflammatory therapy. Biochem Pharmacol 15; 68(6):1171–1185Google Scholar
  25. 25.
    Felson DT, Nevitt MC (1998) The effects of estrogen on osteoarthritis. Curr Opin Rheumatol 10(3):269–272PubMedCrossRefGoogle Scholar
  26. 26.
    Sarrel PM (1990) Sexuality and menopause. Obstet Gynecol 75(4Suppl):26S–30S; discussion 31S–35SGoogle Scholar
  27. 27.
    Kicovic PM, Cortes-Prieto J, Milojevic S, Haspels AA, Aljinovic A (1980) The treatment of postmenopause vaginal atrophy with Ovestin vaginal cream or suppositories: clinical endocrinological and safety aspects. Maturitas 14:23–31Google Scholar
  28. 28.
    Guttuso T Jr, Kurlan R, McDermott MP, Kieburtz K (2003) Gabapentin’s effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 101(2):337–345PubMedCrossRefGoogle Scholar
  29. 29.
    Faure ED, Chantre P, Mares P (2002) Effects of a standardized soy extract on hot flushes: a multicenter double-blind, randomized, placebo-controlled study. Menopause 9(5):329–334PubMedCrossRefGoogle Scholar
  30. 30.
    Kongnyuy EJ, Norman RJ, Flight IHK, Rees MC (2005) Oestrogen and progestogen hormone replacement therapy for perimenopausal and post-menopausal women: weight and body fat distribution. Cochrane Database of Systematic Reviews, Issue 3. Art. no.: CD001018. doi: 10.1002/14651858
  31. 31.
    Sanchanta P, Saenphet K, Saenphet S, Aritajat S, Wongsawad C (2005) Toxicological study of aqueous and ethanolic extracts from Pueraria mirifica Airy Shaw and Suvatabandhu on male rats. In: Brovelli E, Chansakaow S, Farias D et al (eds) III WOCMAP congress on medicinal and aromatic plants—volume 5: quality, effectiveness, safety, processing and trade in medicinal and aromatic plants. International Society for Horticultural Science, Leuven, BelgiumGoogle Scholar
  32. 32.
    Egeland GM, Kuller LH, Matthews KA, Kelsey SF, Cauley J, Guzick D (1990) Hormone replacement therapy and lipoprotein changes during early menopause. Obstet Gynecol Nov 76(5 pt 1):776–782Google Scholar
  33. 33.
    Godsland IF (2001) Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974–2000. Fertil Steril 75:898–915PubMedCrossRefGoogle Scholar
  34. 34.
    Irwig L, Glaszious P, Wilson A, Macaskill P (1991) Estimating an individual’s true cholesterol level and response to intervention. JAMA 266:1678–1685PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Phongthorn Virojchaiwong
    • 1
    Email author
  • Visut Suvithayasiri
    • 1
  • Arunporn Itharat
    • 2
  1. 1.Department of Obstetrics and GynecologyBMA Medical College and Vajira HospitalBangkokThailand
  2. 2.Applied Thai Traditional Medicine Center, Faculty of MedicineThammasat UniversityPathumthaniThailand

Personalised recommendations